Association of CD34 Positive Cell Count with Chronic Graft Versus Host Disease in patients with Acute Myeloid Leukemia who had Allogeneic Peripheral Blood Stem Cell Transplantation

Abstract

Acute myeloid leukemia (AML) is characterized by an increase in the number of myeloid cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic insufficiency (granulocytopenia, thrombocytopenia, or anemia) with or without leukocytosis. Allogeneic and Autologous HSCT have been an established option for consolidation for more than two decades. Prospective randomized trials have not shown auto graft to be superior to chemotherapy but it is an effective approach. Allografting produces the best antileukemic effect of any treatment in any risk or age subgroup.There is general consensus that patients who have good risk disease do not require transplantation and patients with poor risk disease do benefit even though the post transplant survival is still only 30% to 40%. The debate focuses on the 60% of patients who have intermediate risk disease. G-CSF-mobilized PBSC are increasingly used instead of BM cells for G-CSF-mobilized PBSC are increasingly used instead of BM cells for allogeneic transplantation because they